EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access

Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study

Björn Pasternak iD, Peter Ueda, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Viktor Wintzell, Mads Melbye, Henrik Svanström

BMJ · 29.08.2019 · l4772

DOI: 10.1136/bmj.l4772 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift BMJ, online erschienen am 29.08.2019. Verfasst von Björn Pasternak und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, 171 76 Stockholm, Sweden bjorn.pasternak@ki.se. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the cardiovascular effectiveness of sodium glucose cotransporter 2 (SGLT2) inhibitors in routine clinical practice.

Design

Cohort study using data from nationwide registers and an active-comparator new-user design.

Setting

Denmark, Norway, and Sweden, from April 2013 to December 2016.

Participants

20 983 new users of SGLT2 inhibitors and 20 983 new users of dipeptidyl peptidase 4 (DPP4) inhibitors, aged 35-84, matched by age, sex, history of major cardiovascular disease, and propensity score. Main outcome measures Primary outcomes were major cardiovascular events (composite of myocardial infarction, stroke, and cardiovascular death) and heart failure (hospital admission for heart failure or death due to heart failure). Secondary outcomes were the individual components of the cardiovascular composite and any cause death. In the primary analyses, patients were defined as exposed from treatment start throughout follow-up (analogous to intention to treat); additional analyses were conducted with an as-treated exposure definition. Cox regression was used to estimate hazard ratios.

Results

Mean age of the study cohort was 61 years, 60% were men, and 19% had a history of major cardiovascular disease. Of the total 27 416 person years of follow-up in the SGLT2 inhibitor group, 22 627 (83%) was among patients who initiated dapagliflozin, 4521 (16%) among those who initiated empagliflozin, and 268 (1%) among those who initiated canagliflozin. During follow-up, 467 SGLT2 inhibitor users (incidence rate 17.0 events per 1000 person years) and 662 DPP4 inhibitor users (18.0) had a major cardiovascular event, whereas 130 (4.7) and 265 (7.1) had a heart failure event, respectively. Hazard ratios were 0.94 (95% confidence interval 0.84 to 1.06) for major cardiovascular events and 0.66 (0.53 to 0.81) for heart failure. Hazard ratios were consistent among subgroups of patients with and without history of major cardiovascular disease and with and without history of heart failure. Hazard ratios for secondary outcomes, comparing SGLT2 inhibitors with DPP4 inhibitors, were 0.99 (0.85 to 1.17) for myocardial infarction, 0.94 (0.77 to 1.15) for stroke, 0.84 (0.65 to 1.08) for cardiovascular death, and 0.80 (0.69 to 0.92) for any cause death. In the as-treated analyses, hazard ratios were 0.84 (0.72 to 0.98) for major cardiovascular events, 0.55 (0.42 to 0.73) for heart failure, 0.93 (0.76 to 1.14) for myocardial infarction, 0.83 (0.64 to 1.07) for stroke, 0.67 (0.49 to 0.93) for cardiovascular death, and 0.75 (0.61 to 0.91) for any cause death.

Conclusions

In this large Scandinavian cohort, SGLT2 inhibitor use compared with DPP4 inhibitor use was associated with reduced risk of heart failure and any cause death, but not with major cardiovascular events in the primary intention-to-treat analysis. In the additional as-treated analyses, the magnitude of the association with heart failure and any cause death became larger, and a reduced risk of major cardiovascular events that was largely driven by the cardiovascular death component was observed. These data help inform patients, practitioners, and authorities regarding the cardiovascular effectiveness of SGLT2 inhibitors in routine clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AgedDenmarkDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedMyocardial InfarctionNorwayRegistriesSodium-Glucose Transporter 2 InhibitorsStrokeSweden

Substanzen

Dipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, 171 76 Stockholm, Sweden bjorn.pasternak@ki.se.
  • Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
  • Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, 171 76 Stockholm, Sweden.
  • Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
  • Swedish National Diabetes Register, Västra Götalandsregionen, Gothenburg, Sweden.
  • Health Metrics, Department of Public Health and Community Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

ORCID-Profile: Björn Pasternak

Zitieren

APA

Pasternak, B., Ueda, P., Eliasson, B., Svensson, A. M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., Wintzell, V., Melbye, M., & Svanström, H. (2019). Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ, l4772. https://doi.org/10.1136/bmj.l4772

Vancouver

Pasternak B, Ueda P, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, et al. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ. 2019:l4772. doi:10.1136/bmj.l4772

BibTeX
@article{Pasternak2019,
  author = {Pasternak, Björn and Ueda, Peter and Eliasson, Björn and Svensson, Ann-Marie and Franzén, Stefan and Gudbjörnsdottir, Soffia and Hveem, Kristian and Jonasson, Christian and Wintzell, Viktor and Melbye, Mads and Svanström, Henrik},
  title = {Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study},
  journal = {BMJ},
  year = {2019},
  pages = {l4772},
  doi = {10.1136/bmj.l4772}
}
Kostenlos starten →